Pharma Foods International Co., Ltd. (2929.T)
JPY 902.0
(2.38%)
JPY 902.0
(2.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 24.98 Billion JPY | -6.07% |
| 2023 | 26.6 Billion JPY | 10.44% |
| 2022 | 24.08 Billion JPY | 92.99% |
| 2021 | 12.48 Billion JPY | 140.55% |
| 2020 | 5.18 Billion JPY | 17.51% |
| 2019 | 4.41 Billion JPY | 82.44% |
| 2018 | 2.42 Billion JPY | 7.5% |
| 2017 | 2.25 Billion JPY | 130.72% |
| 2016 | 975.82 Million JPY | 241.38% |
| 2015 | 285.84 Million JPY | 17.52% |
| 2014 | 243.23 Million JPY | -39.69% |
| 2013 | 403.28 Million JPY | -3.8% |
| 2012 | 419.2 Million JPY | 249.63% |
| 2011 | 119.9 Million JPY | -19.81% |
| 2010 | 149.52 Million JPY | -58.29% |
| 2009 | 358.45 Million JPY | 88.69% |
| 2008 | 189.97 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 26.91 Billion JPY | -3.24% |
| 2024 Q4 | 24.98 Billion JPY | -7.16% |
| 2024 Q1 | 27.99 Billion JPY | 5.23% |
| 2024 Q2 | 27.81 Billion JPY | -0.63% |
| 2023 Q1 | 27.98 Billion JPY | 16.18% |
| 2023 FY | 26.6 Billion JPY | 10.44% |
| 2023 Q2 | 28.12 Billion JPY | 0.5% |
| 2023 Q3 | 27.9 Billion JPY | -0.76% |
| 2023 Q4 | 26.6 Billion JPY | -4.68% |
| 2022 FY | 24.08 Billion JPY | 92.99% |
| 2022 Q3 | 23.17 Billion JPY | 31.87% |
| 2022 Q4 | 24.08 Billion JPY | 3.93% |
| 2022 Q1 | 21.2 Billion JPY | 69.91% |
| 2022 Q2 | 17.57 Billion JPY | -17.12% |
| 2021 Q2 | 11.94 Billion JPY | 7.04% |
| 2021 Q4 | 12.48 Billion JPY | 5.32% |
| 2021 FY | 12.48 Billion JPY | 140.55% |
| 2021 Q1 | 11.16 Billion JPY | 115.16% |
| 2021 Q3 | 11.85 Billion JPY | -0.83% |
| 2020 Q3 | 5.31 Billion JPY | 2.59% |
| 2020 Q1 | 5.47 Billion JPY | 24.03% |
| 2020 FY | 5.18 Billion JPY | 17.51% |
| 2020 Q2 | 5.17 Billion JPY | -5.45% |
| 2020 Q4 | 5.18 Billion JPY | -2.33% |
| 2019 Q4 | 4.41 Billion JPY | 9.34% |
| 2019 FY | 4.41 Billion JPY | 82.44% |
| 2019 Q1 | 5.07 Billion JPY | 109.55% |
| 2019 Q2 | 4.3 Billion JPY | -15.11% |
| 2019 Q3 | 4.03 Billion JPY | -6.2% |
| 2018 Q1 | 2.81 Billion JPY | 25.15% |
| 2018 Q3 | 2.5 Billion JPY | -1.69% |
| 2018 Q2 | 2.54 Billion JPY | -9.66% |
| 2018 FY | 2.42 Billion JPY | 7.5% |
| 2018 Q4 | 2.42 Billion JPY | -3.29% |
| 2017 Q4 | 2.25 Billion JPY | -7.76% |
| 2017 FY | 2.25 Billion JPY | 130.72% |
| 2017 Q1 | 1.59 Billion JPY | 63.51% |
| 2017 Q2 | 2.69 Billion JPY | 68.91% |
| 2017 Q3 | 2.44 Billion JPY | -9.44% |
| 2016 FY | 975.82 Million JPY | 241.38% |
| 2016 Q1 | 1.56 Billion JPY | 448.19% |
| 2016 Q2 | 1.4 Billion JPY | -10.2% |
| 2016 Q3 | 1.1 Billion JPY | -21.55% |
| 2016 Q4 | 975.82 Million JPY | -11.6% |
| 2015 Q1 | 244.27 Million JPY | 0.43% |
| 2015 Q3 | 320.31 Million JPY | -3.71% |
| 2015 Q4 | 285.84 Million JPY | -10.76% |
| 2015 Q2 | 332.64 Million JPY | 36.18% |
| 2015 FY | 285.84 Million JPY | 17.52% |
| 2014 Q2 | 342.22 Million JPY | -1.64% |
| 2014 FY | 243.23 Million JPY | -39.69% |
| 2014 Q4 | 243.23 Million JPY | 72.0% |
| 2014 Q3 | 141.41 Million JPY | -58.68% |
| 2014 Q1 | 347.92 Million JPY | -13.73% |
| 2013 Q3 | 306.42 Million JPY | -2.7% |
| 2013 Q4 | 403.28 Million JPY | 31.61% |
| 2013 FY | 403.28 Million JPY | -3.8% |
| 2013 Q1 | 310.33 Million JPY | -25.97% |
| 2013 Q2 | 314.92 Million JPY | 1.48% |
| 2012 Q3 | 300.41 Million JPY | 8.82% |
| 2012 FY | 419.2 Million JPY | 249.63% |
| 2012 Q1 | 107.65 Million JPY | -10.21% |
| 2012 Q4 | 419.2 Million JPY | 39.54% |
| 2012 Q2 | 276.07 Million JPY | 156.44% |
| 2011 Q1 | 117.03 Million JPY | -21.73% |
| 2011 Q4 | 119.9 Million JPY | 20.01% |
| 2011 FY | 119.9 Million JPY | -19.81% |
| 2011 Q3 | 99.9 Million JPY | 2.57% |
| 2011 Q2 | 97.39 Million JPY | -16.78% |
| 2010 Q1 | 146.46 Million JPY | -59.14% |
| 2010 Q3 | 142.67 Million JPY | -3.56% |
| 2010 FY | 149.52 Million JPY | -58.29% |
| 2010 Q4 | 149.52 Million JPY | 4.8% |
| 2010 Q2 | 147.94 Million JPY | 1.01% |
| 2009 Q3 | 158.79 Million JPY | -5.8% |
| 2009 Q2 | 168.57 Million JPY | 0.0% |
| 2009 Q4 | 358.45 Million JPY | 125.73% |
| 2009 FY | 358.45 Million JPY | 88.69% |
| 2008 FY | 189.97 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.681% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 96.674% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 84.796% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -636.028% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 41.709% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 10.328% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 94.95% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -395.794% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 59.497% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 18.954% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 37.207% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 19.611% |
| Tsumura & Co. | 132.88 Billion JPY | 81.196% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 37.202% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | -87.922% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 90.905% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 43.412% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 64.659% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 46.713% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -256.819% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 1.773% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | -206.897% |
| MedRx Co., Ltd | 129 Million JPY | -19270.543% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -663.567% |
| Solasia Pharma K.K. | 673 Million JPY | -3612.927% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -3771.09% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 20.372% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 84.763% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -2370.781% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 95.231% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -259.419% |